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Abstract
Background & Aims:	Endoscopic	retrograde	cholangiography	(ERCP)	has	been	con-
sidered	the	gold	standard	for	the	diagnosis	and	follow-	up	of	primary	sclerosing	chol-
angitis,	but	 it	has	been	 replaced	by	 less	 invasive	magnetic	 resonance	 imaging	and	
cholangiopancreatography	(MRI-	MRCP).	However,	the	role	of	these	two	techniques	
in	the	evaluation	of	disease	activity	and	severity	needs	to	be	elucidated.
Methods:	Patients	with	primary	sclerosing	cholangitis	(n:	48,	male	31,	median	age:	
35.7;	28.0-	44.2)	who	underwent	ERCP	and	MRI-	MRCP	within	±3	months	for	diagno-
sis	or	follow-	up,	were	reviewed.	ERCP	and	MRI-	MRCP	images	were	scored	using	the	
modified	Amsterdam	score.	Serum	and	biliary	cytology	markers	of	disease	activity	
and	severity	were	related	to	the	imaging	findings.	Agreement	on	the	assessment	of	
the	ERCP/MRCP	score	was	calculated	by	kappa-	statistics.	Spearman′s	ρ	was	calcu-
lated	when	appropriate.
Results:	The	agreement	between	ERCP	and	MRCP	in	scoring	bile	duct	changes	for	
disease	severity	was	only	moderate	(weighted	kappa:	0.437;	95%	CI:	0.211-	0.644	for	
intra-	and	0.512;	95%	CI:	0.303-	0.720	for	extra-	hepatic	bile	ducts).	ERCP	and	MRCP	
intra-	hepatic	scores	were	associated	to	the	surrogate	marker	alkaline	phosphatase	
(P	=	.02	 for	 both).	A	weak	 correlation	between	MRCP	 score	 for	 extra-	hepatic	 bile	
ducts	 and	 liver	 transplantation/death	 was	 found	 (Spearman’s	 ρ	=	.362,	 95%	 CI:	
0.080-	0.590,	P	=	.022).	A	weak	correlation	between	intra-	(Spearman′s	ρ	=	.322,	95%	
CI:	 0.048-	0.551,	P	=	.022)	 and	 extra-	hepatic	 (Spearman`s	ρ	=	.319,	 95%	CI:	 0.045-	
0.549,	P	=	.025)	peribiliary	enhancement	on	contrast-	enhanced	MRI	and	severity	of	
biliary	cytologic	classification	was	found.
Conclusions:	The	overall	agreement	between	ERCP	and	MRI-	MRCP	in	assessing	dis-
ease	severity	was	moderate	for	intra-	and	extra-	hepatic	bile	ducts.	MRI-	MRCP	seems	
to	have	a	minor	role	as	surrogate	marker	of	disease	activity	and	progression	in	PSC.
K E Y W O R D S
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1  | INTRODUC TION
Primary	 sclerosing	 cholangits	 (PSC)	 is	 a	 chronic	 inflammatory	 and	
fibrotic	disease,	involving	the	intra-	and	extrahepatic	biliary	tree.1,2 
PSC	 leads	 progressively	 to	 end-	stage	 liver	 disease,	 cirrhosis	 and	
eventually	liver	transplantation	(LT)	or	death.3,4	The	disease	also	oc-
curs	in	children	and	young	adults	who	may	need	long-	term	follow-
	up.5	PSC	is	also	a	preneoplastic	condition	with	a	markedly	increased	
risk	for	colon-	and	cholangiocarcinoma.6
Endoscopic	retrograde	cholangiopancreatography	(ERCP)	has	
been	 considered	 the	 gold	 standard	 for	 diagnosis	 of	 PSC,	 since	
it	 provides	 a	 direct	 visualization	of	 the	 entire	 biliary	 tree.7	 The	
main	 cholangiography	 characteristics	 are	 strictures,	 dilatations	
and	pruning	involving	both	intra-	and/or	extrahepatic	bile	ducts.	
ERCP	also	allows	for	the	sampling	of	brush	cytology8,9	as	well	as	
endoscopic	therapy	(ie	dilation	and/or	stenting).	However,	ERCP	
is	an	invasive	procedure	with	an	overall	complication	rate	of	9%-	
12.5%	in	PSC	patients,10	post-	ERCP	pancreatitis	being	the	most	
frequent	 one.10	 A	 meta-	analysis	 has	 shown	 that	 imaging	 with	
magnetic	 resonance	 cholangiopancreatography	 (MRI-	MRCP)	 is	
an	accurate,	non-	invasive	and	cost-	effective	alternative	method	
for	diagnosis	 and	 follow-	up	of	PSC.11	 For	 these	 characteristics,	
MRI-	MRCP	 may	 play	 an	 important	 role,	 especially	 in	 patients	
who	 need	 a	 long	 follow-	up,	 like	 children	 and	 young	 adults.12 
However,	 ERCP	may	 be	 still	 more	 accurate	 in	 the	 detection	 of	
early	changes.13
The	rarity	of	PSC	(prevalence	of	0-	16.2/100.000	inhabitants	per	
year)	and	the	 long	time	period	 (median	time	13-	21	years)	between	
diagnosis	and	strong	end-	points	such	as	LT,	cholangiocarcinoma	or	
death	make	 PSC	 “an	 orphan	 disease”,	 which	 results	 in	 difficulties	
to	plan	 randomized	 clinical	 trial	 on	new	 treatments.	Due	 to	 these	
issues,	 robust	 surrogate	 endpoints	 of	 PSC	 prognosis	 are	 urgently	
needed.14	Alkaline	phosphatase	(ALP)	seems	to	be	the	most	prom-
ising	one.15	Recently,	Boyd	et	al	have	demonstrated	that	advanced	
extra-	hepatic	ERC	changes	and	elevated	aminotransferase	at	diag-
nosis	might	be	risk	factors	for	biliary	neoplasia.	Interestingly,	even	in	
mostly	asymptomatic	patients	(about	80%	at	diagnosis),	about	40%	
had	advanced	disease	and	7%	presented	with	a	 suspicious	or	ma-
lignant	brush	cytology	at	 first	ERCP.9	Furthermore,	a	 recent	study	
has	reported	that	the	majority	of	the	PSC	patients	who	underwent	
MRI-	MRCP	shows	a	 radiological	progression	of	 the	disease	 (about	
58%)	after	a	mean	follow-	up	of	4	years,	 identifying	three	indepen-
dent	predictors	of	evolution:	intrahepatic	biliary	ducts	dilatation,	pa-
renchymal	heterogeneity	and	dysmorphy16;	however,	this	study	lack	
the	ERCP	as	a	reference.
To	our	knowledge,	a	study	evaluating	association	between	ERCP	
and	MRI-	MRCP	findings	with	markers	of	disease	activity	and	sever-
ity	is	still	lacking.
Aims	of	this	study	were	to	evaluate	 in	a	group	of	PSC	patients	
who	underwent	both	ERCP	and	MRI-	MRCP:	 (i)	 the	agreement	be-
tween	ERCP	and	MRCP	in	the	assessment	of	bile	duct	changes	 (ii)	
the	association	between	bile	duct	changes	and	markers	of	PSC	dis-
ease	activity	and	severity	and	(iii)	the	association	between	peribiliary	
enhancement	detected	on	contrast-	enhanced	MRI	and	markers	of	
disease	activity	in	PSC.
2  | MATERIAL S AND METHODS
2.1 | Study design
This	 is	 a	 single-	centre	observational	 longitudinal	 retrospective	co-
hort	study.
2.2 | Setting, time and population
In	Finland,	most	of	the	patients	with	a	suspicious	of	PSC	are	referred	
to	Helsinki	University	Hospital	 (HUH),	where	ERCP	with	brush	cy-
tology	is	still	regarded	the	“gold	standard”	for	the	diagnosis	and	the	
follow-	up	of	the	disease.	Figure	1	shows	the	diagnostic	and	follow-
	up	course	followed	in	our	hospital.9	In	short,	all	patients	suspected	
of	PSC	(ie	based	on	symptoms,	lab	tests,	liver	biopsy	and	MRI-	MRCP)	
undergo	always	ERCP	firstly	to	confirm	or	exclude	the	diagnosis	of	
the	disease	and	secondly	to	assess	the	individual	risk	of	disease	pro-
gression	based	on	brush	cytology.9	The	follow-	up	is	based	on	sever-
ity	of	cholangiographic	changes	and	brush	cytology	results.	Notably,	
patients	with	a	persistently	confirmed	biliary	dysplasia	are	referred	
for	liver	transplantation.17
All	 data	 (ie	 clinical,	 biochemical,	 histology,	 cholangiography	
and	therapy)	are	prospectively	collected	in	the	PSC	registry;	over	
700	subjects	have	been	 included	since	 its	start	 in	2010.	All	PSC	
patients	who	underwent	ERCP	and	MRI-	MRCP	within	±3	months	
for	diagnosis	or	follow-	up	of	the	disease	were	extracted	from	the	
PSC	registry.	The	3-	month	 interval	between	the	two	procedures	
was	chosen	to	minimize	the	classification	bias	due	to	the	progres-
sion	of	the	disease.	PSC	diagnosis	was	based	on	(Figure	1):	(i)	typi-
cal	cholangiographic	features	of	PSC	(ie	focal	or	diffuse	strictures	
and	dilatations	of	the	biliary	tree),	associated	with	(ii)	elevation	of	
cholestatic	 liver	 enzymes	 (ie	 S-ALP),	 (iii)	 negative	 antimitochon-
drial	antibodies	(AMA)	and	eventually	(iv)	histology	suggestive	or	
Key points
•	 The	agreement	between	MRCP	and	ERCP	in	the	evalua-
tion	 of	 the	 severity	 of	 biliary	 changes	 in	 PSC	 is	 only	
moderate.
•	 The	severity	of	biliary	changes	in	MRCP	and	ERCP	is	as-
sociated	 to	 alkaline	 phosphatase,	 which	 has	 been	 re-
garded	as	a	surrogate	marker	of	prognosis	only	in	PSC.
•	 Peribiliary	enhancement	in	MRI	shows	weak	correlation	
with	severity	of	biliary	cytologic	classification	in	PSC.
•	 The	severity	of	extra-hepatic	biliary	changes	on	MRCP	
images	 shows	 only	weak	 correlation	with	 strong	 end-
points	(ie	liver	transplantation	and	death)	in	PSC.
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typical	for	PSC	(v)	presence	of	IBD;	liver	histology	and/or	presence	
of	IBD	were	not	mandatory	for	the	diagnosis	of	PSC.	Patients	with	
secondary	sclerosing	cholangitis	and	 IgG4	associated	cholangitis	
were	excluded.
2.3 | ERCP procedures and images
All	 the	 procedures	were	 performed	 by	 the	 same	 experienced	 en-
doscopists	 (M.F.,	K.J.,	A.T.)	with	the	patient	 in	prone	position	with	
the	 assistance	 of	 an	 anesthesiologist.	 Cannulation	was	 performed	
using	 a	 papillotomy	 knife	 (Jagtome	 RX;	 Boston	 Scientific,	 Miami,	
Florida,	USA®)	and	a	0.035-	in,	450	cm	guide	wire	(Jagwire;	Boston	
Scientific®).	After	a	successful	cannulation,	biliary	papillotomy	was	
performed.	 Afterwards,	 a	 balloon	 catheter	 was	 inserted	 into	 the	
common	hepatic	bile	duct,	and	contrast	was	injected	to	visualize	the	
intrahepatic	bile	ducts.	Then	the	balloon	was	moved	downwards	to	
visualize	the	extra-	hepatic	bile	ducts.	All	the	images	were	obtained	
from	 four	 different	 planes	 to	 visualize	 the	 entire	 biliary	 tree.	 The	
brush	cytology	was	routinely	collected	from	both	intra-	and	extra-
hepatic	bile	ducts	in	all	the	patients.	Patients	were	monitored	after	
the	procedure	for	10	hours	and	possible	complications	treated	ap-
propriately.	All	ERCP	images	were	scored	(M.F.,	K.J.,	A.T.)	using	the	
modified	Amsterdam	PSC	score	(Table	1).	This	score	was	elaborated	
in	2001	to	describe	severity	of	the	bile	duct	changes	on	cholangio-
graphy18	and	it	has	been	later	shown	to	also	be	a	reliable	prognostic	
model.19,20	A	slight	modification	for	intra-	hepatic	score	was	made	in	
our	clinic,	that	is,	intrahepatic	score	I	was	divided	into	two	catego-
ries,	to	classify	early	changes	more	accurately	(Table	1).
2.4 | Cytology
All	cytology	samples	were	reviewed	in	consensus	by	two	experienced	
pathologists	 (S.B.	and	J.A.),	and	the	following	parameters	were	re-	
scored9,21:	 (i)	biliary-	neutrophils	 inflammation	 (0	=	absent,	1	=	mild,	
2	=	high),	(ii)	intra-	epithelial	leucocytes	(IEL;	0	=	absent,	1	=	present)	
and	(iii)	cytology	classification	after	Papanicolau	staining	(1	=	normal	
epithelium,	2	=	benign	atypia,	3	=	mild	suspicion	of	neoplasia,	cyto-
logically	 corresponding	 to	 low-	grade	 dysplasia,	 4	=	high	 suspicion	
of	 neoplasia,	 cytologically	 corresponding	 to	 high-	grade	 dysplasia,	
5	=	malignancy,	cytologically	corresponding	to	carcinoma).
2.5 | MRI- MRCP
Magnetic	 resonance	 imaging	examinations	were	performed	on	1.5	
(Avanto,	 Avanto	 Fit,	 Aera	 or	 Symphony	 Tim	 Siemens	 Healthcare,	
Erlangen,	Germany®;	 Signa	HDxt	or	Optima	MR450w	GE	Medical	
Systems,	 Milwaukee,	 Wis®)	 or	 3.0	 T	 scanners	 (Verio,	 Siemens	
Healthcare,	 Erlangen,	 Germany®).	 Fasting	 for	 at	 least	 3	hours	 be-
fore	 examination	was	 required.	Pineapple	 juice	 (200	mL	5-	10	min-
utes	before	the	examinations)	was	used	as	a	negative	oral	contrast	
agent	 to	 diminish	 the	 signal	 of	 the	 bowel	 lumen	 and	 to	 improve	
visualization	of	 the	pancreatic-	biliary	 systems.	 The	 imaging	proto-
col	included	coronal	and	axial	T2-	weighted	sequences,	an	axial	T2-	
weighted	sequence	with	fat-	suppression,	axial	 in	and	out	of	phase	
T1-	weighted	 gradient	 echo	 sequence	 and	 diffusion-	weighted	 se-
quences	with	three	b-	values	(50,	400	and	800)	and	ADC	map.	MRCP	
images	 included	 a	 respiratory	 triggered	 3D	 heavily	 T2-	weighted	
F IGURE  1 Diagnosis	and	follow-	up	in	patients	with	primary	sclerosing	cholangitis	at	Helsinki	University	Hospital
PATIENT WITH SUSPICION OF PSC
• Clinical (Symptoms/Signs, + IBD)
• Biochemical (elevated S-ALP)
• AMA negave
• + Liver biopsy   
MRI-MRCP
ERCP:
• Modified Amsterdam PSC score
• Brush cytology + DNA-Flow cytometry
• Modified Amsterdam PSC score < 3
• Brush cytology benign
Ultra-sound + ERCP every 3 years
• Modified Amsterdam PSC score < 3
• Brush cytology benign
• Modified Amsterdam PSC score > 3
• Brush cytology:
Benign
ERCP and MRI-MRCP
1-2 years
Benign
Aneuplody
ERCP and
MRI-MRCP
6-12 months
Dysplasia 
+ Aneuplody
ERCP and
MRI-MRCP
3 months
• Repeatedly confirmed dysplasia/aneuploidy
• No suspicion of cancer at imaging Evaluaon for liver transplantaon
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sequence	 in	 the	coronal	plane	and	a	breath-	hold	 thick	slab	single-	
shot	heavily	T2-	weighted	sequence	 in	coronal	and	oblique	coronal	
projections.	Contrast-	enhanced	images	were	acquired	with	an	axial,	
fat-	suppressed	 T1-	weighted	 sequence	 before	 and	 after	 0.2	mL/kg	
body	weight	of	Gd-	DOTA	(Dotarem;	Guerbet,	Aulnay-	sous,	France®),	
with	hepatic	arterial,	portal	and	equilibrium	phase	acquisitions.	Only	
registry	cases	with	both	MRI	and	MRCP	were	included	in	the	pro-
ject.	All	 the	MRI-	MRCP	cholangiography	 images	were	 reviewed	 in	
consensus	by	two	experienced	abdominal	radiologists	(K.L.	and	E.L.),	
blinded	to	clinical	data	and	ERCP	results.	For	the	study	purpose,	the	
images	were	 re-	scored	 using	 the	modified	Amsterdam	PSC	 score,	
to	objectively	 compare	 the	biliary	 changes	detected	 in	MRCP	and	
ERCP.	The	presence	and	the	degree	of	the	peribiliary	enhancement	
was	also	re-	scored	when	MRI	with	contrast	was	available,	as	follows:	
<2,	2-	6,	>6	mm.16
2.6 | Study protocol
All	 the	 demographic	 (ie	 gender,	 age)	 and	 clinical	 (ie	 associated	 in-
flammatory	 bowel	 disease	 [IBD],	 overlapping	 with	 autoimmune	
hepatitis	 [PSC/AIH],	 other	 associated	 immunologic	 disorders)	 data	
were	collected.	ALP,15	serum	alanine	aminotransferase	(ALT),9	serum	
Carcino-	Embryonic	Antigen	(CEA),21,22	serum	Carbohydrate	Antigen	
19-	9	(CA19-	9),21,23	biliary-neutrophils,	IEL,	cytology	classification9,21 
were	used	as	surrogate	markers	of	disease	activity	and	severity.	The	
patient’s	outcome	(ie	need	of	LT	and	death)	was	also	evaluated	by	
October	2016.
2.7 | Statistical analysis
The	categorical	variables	were	expressed	as	the	number	of	events	
or	rate	with	percentage	and	the	continuous	variables	as	median	
with	 interquartile	range	(IQR)	or	25-	75th	percentiles.	The	modi-
fied	Amsterdam	PSC	score	was	grouped	into	three	categories	(ie	
0	=	no	 changes,	 1-	2	=	mild	 changes	 and	 3-	4	=	severe	 changes).	
Peribiliary	 enhancement	was	 classified	 as	 no	 enhancement,	 en-
hancement	<2	mm	and	enhancement	≥2	mm	because	there	were	
few	cases	with	≥6	mm	group	 (n	=	3).	Agreement	between	ERCP	
and	 MRCP	 modified	 Amsterdam	 PSC	 score	 was	 tested	 with	
weighted	kappa-	statistic	with	quadrate	weights.	The	McNemar-	
Bowker	 test	 was	 used	 to	 evaluate	 differences	 in	 pair	 ordinal	
variables.	 Differences	 between	 variables	 were	 tested	 with	 the	
Fisher′s	 exact	 test	 when	 categorical,	 with	 the	 linear-	by-	linear	
association	 test	when	ordinal	 and	with	 the	Mann-	Whitney	Test	
when	 continuous.	 The	 Spearman′s	 ρ	 was	 calculated	 for	 ordinal	
variables	 with	 bootstrapped	 (500	 replications)	 95%	 confidence	
intervals	(CI).
2.8 | Ethical consideration
In	 Finland	patient	 consent	 to	MRI-	MRCP	 and	ERCP	procedures	 is	
obtained	orally.	The	Local	Ethics	Committee	of	Helsinki	University	
Hospital	 for	 Internal	 Medicine,	 has	 approved	 the	 study	 protocol,	
number 278/13/03/01/2009.
3  | RESULTS
3.1 | Baseline characteristics
The	baseline	characteristics	are	summarized	in	Table	2.
Forty-	eight	 patients	 with	 MRI-	MRCP	 within	 ±3	months	 from	
ERCP,	 were	 identified	 from	 the	 PSC	 registry	 (male:	 31,	 median	
age	±	IQR	 at	 the	 time	 of	 PSC	 diagnosis:	 30;	 21.0-	41.5,	 median	
age	±	IQR	at	the	time	of	ERCP:	35.7;	28.0-	44.2).	Five	patients	(10%)	
had	an	overlap	with	AIH	and	36	(75%)	had	an	associated	IBD,	mostly	
ulcerative	colitis	(69%).	An	associated	autoimmune	disease	(eg	psori-
asis)	was	seen	in	23%	of	the	cases.
Overall,	57	ERCPs	were	performed	in	these	patients,	45	for	fol-
low-	up	and	12	for	the	diagnosis	of	the	PSC.	Overall,	52	MRIs	and	55	
MRCPs	were	performed	in	these	patients	(Table	2),	in	37	of	the	cases	
before	ERCP.	Dilatation	of	intra-	and/or	extrahepatic	bile	ducts	was	
performed	in	17	procedures	and	in	only	four	cases	MRI-	MRCP	fol-
lowed	ERCP;	however,	in	these	four	cases	modified	Amsterdam	PSC	
score	 on	 MRI-	MRCP	 cholangiography	 changes	 were	 the	 same	 or	
TABLE  1 Modified	Amsterdam	PSC	score
Amsterdam score Modified score Description
Intrahepatic	bile	ducts
 0 0 No	visible	abnormalities
 I 1 Ductular	irregularities
 I 2 Multiple	calibre	
changes;	minimal	
dilatation
 II 3 Multiple	strictures;	
saccular	dilatations,	
decreased	arborisation
 III 4 Only	central	branches	
filled	despite	adequate	
filling	pressure;	severe	
pruning
Extra-	hepatic	bile	ducts
 0 0 No	visible	abnormalities
 I 1 Slight	irregularities	of	
duct	contour,	no	
stricture
 II 2 Segmental	stricture
 III 3 Stricture	of	almost	
entire	length	of	duct
	IV 4 Extremely	irregular	
margins;	diverticulum-	
like	outpouchings
ERCP	 findings	were	 scored	 according	 to	Ponsioen	 et	al.19	 Intrahepatic	
score	I	was	divided	into	two	categories,	to	classify	early	changes	more	
accurately.	A	mean	score	for	intrahepatic	(right	and	left	biliary	ducts)	and	
for	extra-	hepatic	(common	hepatic	duct	and	common	bile	duct)	was	cal-
culated	separately.	The	final	score	was	grouped	into	three	categories:	0:	
no	changes,	1-	2:	mild	disease,	3-	4:	severe	disease.
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even	higher	 than	that	one	detected	on	ERCP	cholangiography.	No	
patient	had	post	ERCP-	cholangitis.
3.2 | ERCP- MRCP modified Amsterdam PSC 
score agreement
The	overall	percentage	of	agreement	between	ERCP	and	MRCP	in	de-
tecting	any	PSC	changes	was	98%	(54/55)	for	intrahepatic	bile	ducts	
and	78%	(43/55)	for	extra-	hepatic	bile	ducts	(Table	3).	The	agreement	
in	scoring	disease	severity	was	only	moderate	for	both	intrahepatic	
(weighted	kappa:	0.437;	95%	CI:	0.211-	0.644)	and	extra-	hepatic	bile	
ducts	(weighted	kappa:	0.512;	95%	CI:	0.303-	0.720).	The	difference	
between	the	ERCP	and	MRCP	scores	were	statistically	significant	for	
extra-	hepatic	bile	ducts	(McNemar-	Bowker	test	P	=	.041),	but	not	for	
intrahepatic	bile	ducts	(McNemar-	Bowker	test	P	=	.499).
3.3 | ERCP- MRCP modified Amsterdam PSC 
score and markers of PSC activity and severity
The	association	between	the	ERCP	score	and	markers	of	PSC	activ-
ity	and	severity	are	summarized	in	Table	4.	We	found	a	statistically	
significant	association	between	the	intrahepatic	score	and	ALP	and	
CA	 19-	9	 levels	 (P = .018 and P	=	.030,	 respectively),	 but	 observed	
no	statistically	significant	association	with	other	markers	of	disease	
activity	 (ie	 ALT,	 biliary-	neutrophils,	 IEL,	 cytological	 classification).	
Similarly,	 no	 other	 association	 between	 extra-	hepatic	 score	 and	
markers	of	disease	activity	and	severity	was	found.
The	association	between	 the	MRCP	score	and	markers	of	PSC	
activity	and	severity	are	summarized	in	Table	5.	Similarly,	we	found	
a	statistically	significant	association	between	the	intrahepatic	score	
and	the	ALP	and	CA	19-	9	level	(P	=	.016	and	P	<	.001,	respectively).	
Moreover,	 association	 was	 also	 seen	 between	 the	 extra-	hepatic	
score	and	the	CA	19-	9	 level	 (P	=	.021),	but	not	with	other	markers	
of	disease	activity	(ie	ALT,	CEA,	biliary-	neutrophils,	IEL	and	cytologic	
classification).	A	weak	correlation	between	MRCP	score	 for	extra-	
hepatic	bile	ducts	and	hard	end-	points	(death,	transplantation)	was	
found	 (Spearman′s	 ρ	=	.362,	 95%	 CI:	 0.080-	0.590,	 P	=	.022),	 but	
not	for	intrahepatic	bile	ducts	(Spearman′s	ρ	=	.175,	95%	CI:	0.122-	
0.442,	P	=	.315).
3.4 | MRI peribiliary enhancement and markers of 
PSC activity and severity
The	association	between	the	peribiliary	enhancement	detected	by	
MRI	and	the	markers	of	PSC	activity	and	severity	are	summarized	
in	Table	6.
Intrahepatic	 peribiliary	 enhancement	 was	 detected	 in	 40/52	
MRIs	 (77%),	 being	 <2	mm	 in	 14	 cases	 and	 ≥2	mm	 in	 26	 cases.	
Extrahepatic	peribiliary	enhancement	was	detected	in	44/52	MRIs	
(85%),	being	<2	mm	in	13	cases	and	≥2	mm	in	31	cases.
A	 weak	 correlation	 between	 MRI	 intra-	 (Spearman′s	 ρ	=	.322,	
95%	 CI:	 0.048-	0.551,	 P	=	.022)	 and	 extrahepatic	 (Spearman′s	
ρ	=	.319,	 95%	 CI:	 0.045-	0.549,	 P	=	.025)	 peribiliary	 enhancement	
and	 cytologic	 classification	was	 found.	No	 association	 statistically	
significant	with	other	markers	of	disease	activity	(ie	ALP,	ALT,	CEA,	
CA19-	9,	biliary-	neutrophils,	IEL)	was	seen.
TABLE  2 Baseline	characteristics	of	the	patients
Patients 48
Male 31/48	(65%)
Median	age	±	IQR	at	PSC	diagnosis,	years 30.5	(21.0-	41.5)
Median	age	±	IQR	at	ERCP,	years 35.7	(28.0-	44.2)
PSC/AIH 5/48	(10%)
IBD 36/48	(75%)
	Male 22/36	(61%)
	UC 25/36	(69%)
	CD 9/36	(25%)
	Unclassified	IBD 2/36	(6%)
Other	autoimmune	diseases 11/48	(23%)
ERCP: 57
One	ERCP 48
Two	ERCP 9
Total	MRI	+	MRCP: 57
One	MRI-	MRCP 48
Two	MRI-	MRCP 9
	MRI 52/57	(91%)a
	MRCP 55/57	(96%)b
Categorical	variables	are	expressed	as	number	or	rate	with	percentage	
(in	brackets).	Age	is	expressed	as	median	with	interquartile	range.
AIH,	autoimmune	hepatitis;	CD,	Crohn′s	disease;	ERCP,	endoscopic	retro-
grade	cholangiopancreatography;	IBD,	inflammatory	bowel	disease;	MRCP,	
magnetic	resonance	cholangiopancreatography;	MRI,	magnetic	resonance	
imaging;	PSC,	primary	sclerosing	cholangitis;	UC,	ulcerative	colitis.
aIn	five	out	of	57	MRI,	contrast	medium	was	not	administrated.
b3D	not	available	in	two	out	of	57	MRCP.
TABLE  3 Agreement	between	ERCP	and	MRCP	in	scoring	 
cholangiographic	changes	using	modified	Amsterdam	PSC	score
Intrahepatic
ERCP score
0 (n = 0) 1- 2 (n = 23) 3- 4 (n = 32)
MRCP	score
 0 0/0	(0%) 1/23	(4%) 0/32	(0%)
	1-	2 0/0	(0%) 13/23	(56%) 6/32	(19%)
	3-	4 0/0	(0%) 9/23	(39%) 26/32	(81%)
Extra- hepatic
ERCP score
0 (n = 11) 1- 2 (n = 33) 3- 4 (n = 11)
MRCP	score
 0 3/11	(27%) 1/33	(3%) 0/11	(0%)
	1-	2 7/11	(64%) 25/33	(76%) 2/11	(18%)
	3-	4 1/11	(9%) 7/33	(39%) 9/11	(82%)
Values	expressed	as	rate	with	percentage	(in	brackets).
ERCP,	endoscopic	retrograde	cholangiography;	MRCP,	magnetic	
resonance	cholangiopancreatography;	PSC,	primary	sclerosing	cholangitis.
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3.5 | Outcome of PSC
The	median	±	IQR	follow-	up	after	ERCP	was	3.5;	3.0-	4.3	years.	During	
the	follow-	up,	11	patients	(23%)	were	transplanted	(five	patients	for	
end-	stage	 liver	 disease	 and	 six	 patients	 for	 suspicion	 of	 neoplasia).	
One	patient	(2%)	died	from	cholangiocarcinoma.	Characteristics	of	the	
seven	patients	with	suspicion	of	malignancy	or	cholangiocarcinoma	
diagnosis	 are	 shown	 in	Table	7.	 ERCP	was	 repeated	 after	 3	months	
from	the	index	ERCP	at	least	once	for	the	confirmation	of	the	finding	
in	all	of	the	patients.	High-	grade	dysplasia	or	cholangiocarcinoma	was	
detected	in	the	explanted	liver	in	5;	in	one	patient,	low-	grade	dyspla-
sia	was	seen.	One	of	six	patients	transplanted	for	suspicion	of	neopla-
sia	died	from	cholangiocarcinoma	after	LT,	and	one	developed	colon	
cancer	with	metastasis	and	is,	however,	still	alive.
4  | DISCUSSION
4.1 | Statement of principle findings
To	our	knowledge,	 this	was	the	first	study	 investigating	the	role	of	
ERCP	and	MRI-	MRCP	in	the	evaluation	of	PSC	disease	activity	and	
severity.	The	main	findings	of	this	study	were:	(i)	The	moderate	agree-
ment	between	MRCP	and	ERCP	in	scoring	the	severity	of	cholangio-
graphic	changes	with	the	modified	Amsterdam	PSC	score,	especially	
for	extra-	hepatic	bile	ducts,	(ii)	Association	between	the	ERCP/MRCP	
score	and	the	serum	levels	of	ALP	and	CA	19-	9,	(iii)	Weak	correlation	
between	MRCP	score	for	extra-	hepatic	bile	ducts	and	liver	transplan-
tation	or	death,	 (iv)	Weak	correlation	between	peribiliary	enhance-
ment	detected	by	MRI	and	severity	of	biliary	cytologic	classification,	
but	not	with	other	markers	of	disease	activity	and	severity.
4.2 | Selection of markers of disease 
activity and severity
Better	surrogate	markers	for	the	evaluation	of	the	disease	activity,	
severity	and	progression	of	the	bile	duct	disease	are	urgently	needed	
in	PSC.14	Many	different	scores	(Child-	Pugh	score,	Model	for	End-	
stage	Liver	Disease,	Mayo	score)	have	been	used	in	different	centres	
for	 risk	 stratification	 and	 evaluation	of	PSC	 severity,	 but	 they	 are	
limited	by	their	short	horizon	so	that	they	predict	better	only	imped-
ing	liver	failure	in	end-	stage	liver	disease.14	So	far,	the	most	promis-
ing	surrogate	markers	have	been	ALP	and	transient	elastography,14 
TABLE  4 Association	between	ERCP	modified	Amsterdam	PSC	score	and	markers	of	PSC	activity	and	severity	(n	=	57)
ERCP modified Amsterdam PSC score
Intrahepatic Extra- hepatic
1- 2 3- 4 P 0 1- 2 3- 4 P
ALP,	UI/L 150 
74-	228
252 
141-	407
.02* 171 
137-	407
197 
127-	357
277 
64-	535
.85
ALT,	UI/L 34 
24-	191
69 
33-	150
.42 59 
23-	137
61 
28-	197
61 
35-	131
.84
CEA,	ng/mL 1.2 
1.0-	1.9
1.5 
1.0-	2.0
.31 1.3 
1.0-	4.2
1.5 
1.0-	1.9
1.2 
1.0-	1.6
.824
CA19-	9,	kU/L 7.0 
4.0-	11.0
10.0 
6.0-	33.2
.03* 9.0 
6.0-	34.0
8.0 
4.7-	14.2
13.0 
9.0-	30.0
.08
Biliary-	neutrophils	inflammation	n	=	55a
 0 n = 8 3	(37%) 5	(62%) 1.00 3	(37%) 4	(50%) 1	(12%) .41
 1 n = 33 14	(42%) 19	(58%) 6	(18%) 19	(58%) 8	(24%)
 2 n = 14 6	(43%) 8	(57%) 2	(14%) 9	(64%) 3	(21%)
Cytologic	classification	n	=	55a
 1 n = 8 4	(50%) 4	(50%) .83 3	(37%) 4	(50%) 1	(12%) .06
 2 n = 40 16	(40%) 24	(60%) 7	(17%) 26	(65%) 7	(17%)
 3 n = 5 1	(20%) 4	(80%) 1	(20%) 1	(20%) 3	(60%)
 4 n = 2 2	(100%) 0	(0%) 0	(0%) 1	(50%) 1	(50%)
Categorical	variables	are	expressed	as	number	of	events	with	percentage	(in	brackets).	Continuous	variables	are	expressed	as	median	with	25-	75th	
percentiles.	n,	number	of	patients	tested.
Biliary-	neutrophils	inflammation:	0	=		absent,	1	=		mild,	2	=		high.
Cytology	classification	after	Papanicolau	staining:	1	=	normal	epithelium,	2	=	benign	atypia,	3	=	mild	suspicion	of	neoplasia,	cytologically	corresponding	
to	low-	grade	dysplasia,	4	=	high	suspicion	of	neoplasia,	cytologically	corresponding	to	high-	grade	dysplasia,	5	=		malignancy,	cytologically	correspond-
ing	to	carcinoma.
ALP,	alkaline	phosphatase;	ALT,	alanine	aminotransferase;	CA19-	9,	Carbohydrate	Antigen	19-	9;	CEA,	Carcino-	Embryonic	Antigen;	ERCP,	endoscopic	
retrograde	cholangiography;	PSC,	primary	sclerosing	cholangitis.
aIn	two	procedures,	cytology	sample	was	not	enough	for	evaluation.
*P < .05.
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but	the	latter	is	not	routinely	performed	in	PSC	patients.	Recently,	
it	has	been	reported	that	ALP	is	able	to	discriminate	between	PSC	
patients	with	a	good	and	a	poor	prognosis,15	making	this	enzyme	one	
of	 the	most	 promising	 surrogate	markers	 for	 clinical	 trials	 in	PSC.	
Enhanced	liver	fibrosis	(ELF)	test,	a	panel	incorporating	three	direct	
serum	markers	of	fibrosis	in	an	algorithm	(hyaluronic	acid,	tissue	in-
hibitor	 of	metalloproteinases-	1	 and	 amino-	terminal	 pro-	peptide	 of	
type	III	pro-	collagen),	has	been	recently	shown	to	predict	transplant-	
free	survival	in	PSC	patients	in	two	independent	Norwegian	PSC	co-
horts24	and	in	one	Dutch	multi-	centre	study,25	but	this	result	needs	
to	be	confirmed	in	further	prospective	patients′	cohort.	In	a	recent	
study,	it	has	been	showed	that	elevated	liver	enzymes,	CEA,	CA	19-	
9,	advanced	bile	duct	disease,	inflammation	or	suspicious	of	neopla-
sia	in	brush	cytology	is	a	risk	factor	for	cholangiocarcinoma.21	The	
tumour	marker	CA	19-	9	combined	with	imaging	study	has	been	pro-
posed	as	a	screening	test	for	cholangiocarcinoma	in	PSC	patients.26 
However,	it	is	important	to	consider	that	CA	19-	9,	although	exten-
sively	used	in	clinical	practice,27	has	a	poor	sensitivity28	and	speci-
ficity29	 for	 the	 diagnosis	 of	 cholangiocarcinoma	 in	 PSC	 patients,	
which	hampers	the	value	of	this	parameter.23	Finally,	Färkkilä	et	al	
have	 recently	 reported	a	 correlation	between	biliary	 inflammation	
(eg	biliary-neutrophils)	and	biliary	dysplasia	in	PSC	patients	(Farkkila	
MA,	UEGW,	2016),	highlighting	still	the	important	role	of	ERCP	with	
brush	cytology	in	the	follow-	up	of	patients	with	PSC.
4.3 | MRCP and ERCP scores
Magnetic	resonance	cholangiopancreatography	is	now	the	first	diag-
nostic	step	in	patients	with	a	suspicion	of	PSC	due	to	its	good	accu-
racy	and	because	it	is	a	non-	invasive	and	cost-	effective	procedure.30 
However,	in	our	centre,	ERCP	with	the	balloon	occlusion	technique	
is	always	performed	in	all	the	patients	with	suspected	PSC,	mostly	
for	 its	 higher	 accuracy	 in	 detecting	 early	 changes.13	 Indeed,	 diag-
nosis	of	small-	duct	PSC	can	be	extremely	challenging	without	high-	
quality	 ERCP.	 Secondly,	 ERCP	 allows	 to	 assess	 the	 individual	 risk	
of	 disease	 progression	 based	 on	 brush	 cytology.9	 A	meta-	analysis	
including	six	studies	published	between	2000	and	2006	concluded	
that	 MRCP	 has	 a	 very	 high	 specificity	 (Sp	 0.94;	 0.86-	0.98)	 and	
TABLE  5 Association	between	MRCP	modified	Amsterdam	PSC	score	and	markers	of	PSC	activity	and	severity	(n	=	55)
MRCP modified Amsterdam PSC score
Intrahepatic Extra- hepatic
1- 2 3- 4 P 0 1- 2 3- 4 P
ALP,	UI/L 150 
74-	266
228 
139-	454
.02* 174 
146-	244
204 
128-	383
228 
82-	434
.94
ALT,	UI/L 34 
25-	192
74 
40-	159
.54 28 
15-	105
71 
28-	198
69 
31-	136
.26
CEA,	ng/mL 1.5 
1.0-	1.9
1.3 
1.0-	2.1
.82 1.4 
0.3-	4.4
1.5 
1.0-	2.1
1.2 
1.0-	2.0
.96
CA19-	9,	kU/L 6.0 
0.0-	8.0
11.0 
8.0-	21.0
<.001* 3.0 
0.0-	6.0
8.5 
5.8-	15.3
10.0 
7.0-	57.0
.02*
Biliary-	neutrophils	inflammation	n	=	52a
 0 n = 7 3	(43%) 4	(57%) 1.00 2	(28%) 4	(57%) 2	(28%) .71
 1 n = 31 10	(32%) 21	(68%) 0	(0%) 18	(58%) 13	(42%)
 2 n = 14 5	(36%) 9	(64%) 2	(14%) 10	(71%) 2	(14%)
Cytologic	classification	n	=	52a
 1 n = 7 4	(57%) 3	(43%) 1.00 2	(28%) 5	(71%) 1	(14%) .08
 2 n = 39 12	(31%) 27	(69%) 2	(5%) 24	(61%) 13	(33%)
 3 n = 4 0	(0%) 4	(100%) 0	(0%) 2	(50%) 2	(50%)
 4 n = 2 2	(100%) 0	(0%) 0	(0%) 1	(50%) 1	(50%)
Categorical	variables	are	expressed	as	number	of	events	with	percentage	(in	brackets).	Continuous	variables	are	expressed	as	median	with	25-	75th	
percentiles.	n,	number	of	patients	tested.
The	intrahepatic	score	0	was	not	reported	because	only	one	patient	was	included.
Biliary-	neutrophils	inflammation:	0	=	absent,	1	=	mild,	2	=	high.
Cytology	classification	after	Papanicolau	staining:	1	=		normal	epithelium,	2	=		benign	atypia,	3	=		mild	suspicion	of	neoplasia,	cytologically	correspond-
ing	to	low-	grade	dysplasia,	4	=		high	suspicion	of	neoplasia,	cytologically	corresponding	to	high-	grade	dysplasia,	5	=		malignancy,	cytologically	corre-
sponding	to	carcinoma.
ALP,	alkaline	phosphatase;	ALT,	alanine	aminotransferase;	CA19-	9,	Carbohydrate	Antigen	19-	9;	CEA,	Carcino-	Embryonic	Antigen;	MRCP,	magnetic	
resonance	cholangiopancreatography;	PSC,	primary	sclerosing	cholangitis.
aIn	two	procedures,	cytology	sample	was	not	enough	for	evaluation.
*P < .05.
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positive	 likelihood	ratio	(15.5;	6.2-	38.1)	for	the	diagnosis	of	PSC.11 
However,	most	of	the	studies	included	in	this	meta-	analysis	present	
the	following	 limitations:	three	studies	were	retrospective	and	the	
number	of	patients	included	was	small,	gold	standard	was	ambigu-
ous	 in	many	of	 the	 included	 studies	 (in	 some	 study	 percutaneous	
transhepatic	 cholangiography	 was	 considered),	 heterogeneity	 in	
MRI-	MRCP	sequences,	the	lack	of	information	regarding	PSC	sever-
ity	classification,	the	lack	of	the	impact	on	patients’	outcome.	In	this	
study,	we	included	patients	with	a	wide	spectrum	of	the	disease.	The	
agreement	between	ERCP	and	MRCP	in	detecting	any	PSC	changes	
was	as	high	as	98%	and	78%	for	intra-	and	extrahepatic	bile	ducts	re-
spectively.	The	overall	agreement	between	ERCP	and	MRCP	in	scor-
ing	disease	severity	according	to	the	modified	Amsterdam	PSC	score	
was	moderate	for	both	intra-	and	extrahepatic	bile	ducts,	and	MRCP	
tended	to	classify	 the	changes	as	more	severe	compared	to	ERCP,	
especially	 when	 located	 in	 extra-	hepatic	 bile	 ducts.	 This	 finding	
needs	to	be	confirmed	in	further	studies	including	a	control	group	to	
evaluate	the	accuracy	of	MRCP.	The	moderate	agreement	may	also	
be	explained	by	the	poor	inter-	observer	agreement	in	the	evaluation	
of	PSC	disease	severity	already	reported	in	some	studies,31	although	
the	review	of	the	images	was	performed	in	consensus.	Finally,	modi-
fied	Amsterdam	PSC	score	is	not	routinely	used	in	MRCP	evaluation	
in	our	hospital.	We	have	applied	modified	Amsterdam	PSC	score	to	
MRCP	images	only	for	the	study	purpose,	to	compare	objectively	the	
biliary	changes	detected	in	ERCP	and	MRCP	images.	To	our	knowl-
edge,	Amsterdam	PSC	score	has	never	been	validated	for	the	evalu-
ation	of	biliary	changes	in	MRCP	images.	A	further	study	focused	on	
this	issue	would	be	interesting	in	the	future.
Interestingly,	more	severe	changes	detected	by	MRCP	in	extra-	
hepatic	bile	ducts	showed	to	have	a	weak	correlation	with	hard	end-	
points	such	as	liver	transplantation/death.	This	finding	might	suggest	
a	role	of	MRCP	as	a	surrogate	marker	of	poor	prognosis	in	PSC,	but	it	
TABLE  6 Association	between	MRI	peri-	biliary	enhancement	and	markers	of	PSC	activity	and	severity	(n	=	52)
MRI peri- biliary enhancement
Intrahepatic Extra- hepatic
Absent 
12/52 (23)
<2 mm 
14/52 (27)
≥2 mm 
26/52 (50) P
Absent 
8/52 (15)
<2 mm 
13/52 (25) ≥2 mm 31/52 (60) P
ALP,	UI/L 129 
56-	203
204 
138-	447
235 
127-	383
.08 143 
70-	204
192 
148-	349
242 
90-	391
.34
ALT,	UI/L 30 
22-	86
191 
31-	226
62 
32-	103
.06 46 
22-	96
45 
25-	218
57 
33-	137
.55
CEA,	ng/mL 1.6 
1.0-	4.4
1.5 
0.7-	1.9
1.0 
1.0-	1.8
.49 1.5 
1.1-	4.9
1.5 
1.0-	2.0
1.2 
1.0-	1.9
.47
CA19-	9,	kU/L 9.5 
6.2-	15.7
6.5 
2.2-	9.2
10.5 
5.0-	33.2
.07 8.5 
6.0-	16.5
9.0 
1.5-	12.5
9.0 
7.0-	32.0
.46
Biliary-	neutrophils	inflammation	n	=	50a
	0	n	=	6 3	(50%) 2	(33%) 1	(17%) .13 2	(33%) 1	(17%) 3	(50%) .09
 1 n = 30 7	(23%) 6	(20%) 17	(57%) 6	(20%) 8	(27%) 16	(53%)
 2 n = 14 2	(14%) 4	(29%) 8	(57%) 0	(0%) 4	(29%) 10	(71%)
IEL	n	=	50a
 0 n = 17 5	(29%) 4	(23%) 8	(47%) .59 2	(12%) 6	(35%) 9	(53%) 1.00
 1 n = 33 7	(21%) 8	(24%) 18	(54%) 6	(18%) 7	(21%) 20	(61%)
Cytologic	classification	n	=	50a
 1 n = 4 2	(50%) 2	(50%) 0	(0%) .02* 2	(50%) 1	(25%) 1	(25%) .03*
 2 n = 39 10	(26%) 8	(20%) 21	(54%) 6	(15%) 11	(28%) 22	(56%)
 3 n = 5 0	(0%) 2	(40%) 3	(60%) 0	(0%) 1	(20%) 4	(80%)
 4 n = 2 0	(0%) 0	(0%) 2	(100%) 0	(0%) 0	(0%) 2	(100%)
Categorical	variables	are	expressed	as	number	or	rate	with	percentage	(in	brackets).	Continuous	variables	are	expressed	as	median	with	25-	75th	per-
centiles.	n,	number	of	patients	tested.
Biliary-	neutrophils	inflammation:	0	=	absent,	1	=	mild,	2	=	high.
IEL:	0	=	absent,	1	=	present.
Cytology	classification	after	Papanicolau	staining:	1	=	normal	epithelium,	2	=	benign	atypia,	3	=	mild	suspicion	of	neoplasia,	cytologically	corresponding	
to	low-	grade	dysplasia,	4	=	high	suspicion	of	neoplasia,	cytologically	corresponding	to	high-	grade	dysplasia,	5	=	malignancy,	cytologically	correspond-
ing	to	carcinoma.
ALP,	alkaline	phosphatase;	ALT,	alanine	aminotransferase;	CA19-	9,	Carbohydrate	Antigen	19-	9;	CEA,	Carcino-	Embryonic	Antigen;	IEL,	Intra-	epithelial	
lymphocytes;	MRI,	magnetic	resonance	imaging;	PSC,	primary	sclerosing	cholangitis.
aIn	two	procedures,	cytology	sample	was	not	enough	for	evaluation.
*P < .05.
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needs	to	be	confirmed	in	further	prospective	studies.	Severity	of	dis-
ease	evaluated	by	MRCP	was	not	associated	with	biliary	neoplasia.
Intriguingly,	 the	 ERCP	 and	MRCP	 scores	were	 associated	with	
the	serum	ALP	and	CA	19-	9	levels.	Cholangiography	disease	severity	
score,	ALP	and	CA19-	9	might	be	hopefully	combined	all	together	in	
the	future	in	a	model	for	a	clinical	(ie	prognostic	value)	and	scientific	
(ie	surrogate	end-	point	for	clinical	trial)	purpose	in	PSC	patients.
4.4 | MRI peribiliary enhancement
In	 this	 study,	we	 demonstrated	 a	weak	 correlation	 between	 peri-
biliary	enhancement	and	severity	of	biliary	cytologic	classification.	
However,	no	correlation	with	any	of	the	other	non-	invasive	(ie	ALT,	
ALP,	CA19-	9)	or	invasive	(ie	inflammation	in	brush	cytology)	surrogate	
markers	of	PSC	disease	activity	and	severity	was	found.	Contrast-	
enhanced	 T1-	weighted	 sequences	may	 demonstrate	 signs	 of	 peri-
ductal	inflammation	and	thickening	of	the	wall	of	extra-	hepatic	bile	
ducts	in	patients	with	PSC.32	A	possible	explanation	for	this	finding	is	
that	PSC	is	characterized	histologically	by	inflammation	(ie	infiltration	
of	neutrophils,	lymphocytes	and	plasma	cells),	which	is	more	intense	
around	the	bile	ducts.33	This	observation	may	explain	why	peribiliary	
enhancement	did	not	correlate	with	inflammation	detected	in	cytol-
ogy,	which	 is	usually	 located	 into	epithelium	 (ie	biliary-neutrophils	
and	IEL).	Finally,	persistent	inflammation	induces	damage	of	cholan-
giocytes	and	progressive	fibrosis34	and	trough	a	multistep	transition	
(ie	 normal	 epithelium,	 metaplasia,	 dysplasia)	 to	 cholangiocarci-
noma.35	However,	whether	defined	periductal	biliary	 inflammation	
in	the	MRI	(ie	presence	and	thickness)	can	be	used	to	discriminate	
among	 inflammatory,	 preneoplastic	 and	 neoplastic	 lesions	 needs	
to	 be	 confirmed	 in	 the	 future	 in	 other	 large	 prospective	 studies.	
In	 this	 study	peribiliary	enhancement	 thickness	was	classified	 into	 
<2,	2-	6,	>6	mm,	although	 the	 last	 two	groups	were	 finally	merged	
together	(≥2	mm)	because	there	were	only	3	cases	in	>6	mm	group.	
Still,	the	diagnostic	characteristics	of	brush	cytology	are	largely	de-
pendent	 by	 the	definition	of	 “positive	 finding”.	 In	 this	 respect,	 in-
flammation	and	low-	grade	dysplasia	might	be	easily	misleading.	In	a	
study	on	the	accuracy	of	brush	cytology	for	diagnosis	of	cholangio-	
carcinoma	in	patients	with	PSC,	combing	low-	grade	dysplasia,	high-	
grade	dysplasia	and	malignancy	as	“a	positive	finding”	increased	the	
sensitivity	of	the	test	up	to	100%,	reducing	specificity	to	84%.36	A	
recent	meta-	analysis	reported	a	pooled	sensitivity	and	specificity	of	
brush	cytology	for	the	diagnosis	of	cholangio-	carcinoma	in	PSC	pa-
tients	of	43%	(C.I.:	35%-	52%)	and	97%	(C.I.:	95%-	98%)	respectively.28 
In	this	context,	repeated	ERCP	with	brush	cytology8	and	eventually	
DNA	flow-	cytometry37	still	plays	a	pivotal	role	in	screening	and	con-
firmation	of	severe	dysplasia/cholangio-	carcinoma,	 to	guide	thera-
peutic	decisions,	for	example,	LT,9	as	also	suggested	by	the	follow-	up	
of	our	patients	with	suspected	cholangio-	carcinoma.	To	this	respect,	
diagnosis	and	follow-	up	of	PSC	in	our	centre	is	unique	and	peculiar	
(Figure	1)	 compared	 to	 the	 current	 EASL-	ESGE	 guidelines,38	 since	
ERCP	is	performed	in	all	the	patients	with	suspected	PSC	to	confirm	
or	exclude	the	diagnosis	and	then	in	those	with	confirmed	diagnosis	
to	assess	the	individual	risk	of	disease	progression	based	on	brush	
cytology.
4.5 | Strengths and limitations
This	was	 the	 first	 study	 evaluating	 the	 role	 of	 ERCP	 and	MRI-	
MRCP	 in	 the	 assessment	 of	 PSC	 disease	 activity	 and	 severity.	
Patients	with	a	wide	spectrum	of	disease	severity	(ie	mild	and	se-
vere)	were	 included	and	all	MRI-	MRCP	cholangiography	 images	
were	re-	scored	by	two	radiologists	in	consensus.	Similarly,	all	cy-
tologic	samples	were	reviewed	for	signs	of	 inflammation	and/or	
neoplasia	by	two	experienced	pathologists.	We	included	patients	
TABLE  7 Outcome	of	the	seven	PSC	patients	with	suspicion	of	malignancy	or	cholangiocarcinoma
PSC patients with suspicion or malignancy
1 2 3 4 5 6 7
Cytologic	classification	at	
ERCP	index
3 3 3 3 3a 4 4a
Enhancement	on	MRI	
(intra-	and	extrabile	ducts)
<2 mm ≥2	mm ≥2	mm ≥	2	mm ≥2	mm ≥2	mm ≥2	mm
Number	of	ERC	+	brush	
cytology	to	confirm
2 2 1 1 2 1 3
Liver	transplantation + − + + + + +
Finding	in	explanted	liver CC − HGD CC 
Cirrhosis
CC LGD HGD
Outcome Alive Dead Alive Alive Dead Alive Colon	Cancer
Cytology	classification	after	Papanicolau	staining:	1	=	normal	epithelium,	2	=	benign	atypia,	3	=	mild	suspicion	of	neoplasia,	cytologically	corresponding	
to	low-	grade	dysplasia,	4	=	high	suspicion	of	neoplasia,	cytologically	corresponding	to	high-	grade	dysplasia,	5	=	malignancy,	cytologically	correspond-
ing	to	carcinoma.
CC,	cholangiocarcinoma;	ERCP,	endoscopic	retrograde-	cholangiography;	HGD,	high-	grade	dysplasia;	LGD,	low-	grade	dysplasia;	MRI,	magnetic	reso-
nance	imaging;	PSC,	primary	sclerosing	cholangitis.
aAneuploidy	detected.
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in	 whom	 ERCP	 and	 MRI-	MRCP	 had	 been	 performed	 within	
±3	months	of	each	other	to	minimize	the	bias	due	to	the	progres-
sion	of	disease;	this	strict	criterion	is	responsible	of	the	reduction	
in	the	number	of	patients	included	in	this	study,	which	might	have	
introduced	a	selection	bias.	However,	the	number	of	patients	in	
our	study	 is	similar	 to	 the	number	of	patients	 included	 in	other	
series	comparing	the	accuracy	of	ERCP	and	MRCP	in	the	diagno-
sis	of	PSC.11	The	outcome	was	reported	 in	patients	with	a	poor	
prognosis	 (ie	LT	and	death).	However,	 this	study	also	presented	
some	 limitations	 that	 are	 the	 retrospective	 design,	 although	 all	
the	data	regarding	PSC	patients	have	prospectively	been	entered	
into	the	PSC	register	of	our	hospital	since	2010	and	the	absence	
of	a	control	group.
5  | CONCLUSIONS
The	agreement	between	ERCP	and	MRCP	in	scoring	the	disease	se-
verity	is	only	moderate,	especially	for	extra-	hepatic	bile	ducts.	ALP,	
a	surrogate	marker	of	progression	in	PSC,	seems	to	be	associated	to	
the	severity	of	biliary	changes	detected	on	MRCP	and	ERCP	images.	
The	correlation	between	extra-	hepatic	biliary	changes	on	MRCP	im-
ages	and	strong	end-	points	 in	PSC	is	only	weak.	Similarly,	 the	cor-
relation	 between	 peribiliary	 enhancement	 on	 contrast-	enhanced	
MRI	and	biliary	cytologic	classification	 (ie	 inflammation,	neoplasia,	
malignancy)	in	PSC	is	only	weak.	All	together,	these	findings	suggest	
a	minor	role	of	MRI-	MRCP	as	surrogate	marker	of	disease	activity	
and	progression	in	PSC.
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